瘤性EML4-ALK组件抑制生长因子的感知,调节药物耐受性
David Gonzalez-Martinez1, Lee Roth1, Thomas R Mumford1
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Nature communications
|November 3, 2024
概括
在ALK驱动的癌症中,耐药性与EML4-ALK蛋白组合有关. 这些组件抑制受体氨酸激酶 (RTK) 信号传递,但ALK抑制会意外地使RTK重新敏感,通过ERK再激活促进细胞存活.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
背景情况:
- 耐药性是治疗由EML4-ALK融合瘤基因驱动的癌症的一个主要障碍.
- EML4-ALK形成细胞质蛋白凝聚物,但它们在药物反应中的作用尚未完全理解.
研究的目的:
- 研究EML4-ALK组件在向治疗反应中的功能.
- 阐明耐药性的机制,并确定潜在的治疗策略.
主要方法:
- 利用光遗传学和活细胞成像来研究EML4-ALK组件.
- 分析了EML4-ALK,适配蛋白和受体氨酸激酶 (RTK) 信号通路之间的相互作用.
主要成果:
- EML4-ALK组件通过隔离GRB2和SOS1.1等适配器蛋白来抑制RTK信号传输.
- 抑制ALK释放这些适配器,使RTK信号重新敏感,并导致脉动式ERK重新激活.
- 再激活的ERK信号传递,由垂死的细胞中的副质连接体驱动,促进癌细胞的生存.
结论:
- EML4-ALK组件在RTK信号和药物反应中起着调节作用.
- 发现了一种新型的耐受性机制,用于涉及RTK复敏感化和ERK重新激活的向疗法.
- 针对甲状腺信号的组合疗法与ALK抑制一起可以克服耐药性.
更多相关视频
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Loss of Tumor Suppressor Gene Functions
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


